Werewolf Therapeutics is a biopharmaceutical company that develops therapeutics designed to stimulate the body's immune system to treat cancer. Using its PREDATOR platform, the company creates molecules that stimulate adaptive and innate immunity for better immune therapies. The company's lead product candidates, WTX-124 and WTX-330, are conditionally activated Interleukin-2 and Interleukin-12 molecules respectively, for the treatment of advanced solid tumors or relapsed/ refractory tumors or lymphoma.